COMP <GO>
ACAD vs MRK // PIOTROSKI F-SCORE QUALITY
ACADIA Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ACAD 5
— MRK 7
■ METRIC PARITY
LAST: $20.59 (-0.82%) • MKT CAP: $3.58B
piotroski-score
7/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACAD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACAD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 91.70% | 74.80% | +16.90 | ACAD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.90% | 20.70% | -12.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.2x | 15.3x | +15.90 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.94% | 3.42% | -0.48 | MRK | /fcf-yield <GO> |
| Operating Margin | 9.80% | 34.30% | -24.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | 36.50% | 28.10% | +8.40 | ACAD | /net-margins <GO> |
| Revenue Growth (YoY) | 11.90% | 1.30% | +10.60 | ACAD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.26 | 5.19 | +1.07 | ACAD | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.3 | 51.7 | -4.40 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 18.4x | -9.90 | ACAD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.58B | $361.02B | -$357.44B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACAD REV | MRK REV | ACAD GROSS % | MRK GROSS % | ACAD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.07B | $65.01B | 91.7% | 74.8% | $105.1M | $12.36B |
| FY 2024 | $957.8M | $64.17B | 91.5% | 76.3% | $157.2M | $18.10B |
| FY 2023 | $726.4M | $60.12B | — | — | $16.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACAD // BETA —
MRK // BETA 0.92